Tenofovir-induced kidney injury

Area of Science:

• Pharmacology
• Nephrology
• Virology

Background:

• Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor effective against HIV and HBV.
• Early trials showed minimal nephrotoxicity, but later reports indicated potential kidney damage with wider use.

Purpose of the Study:

• To review the pharmacokinetics, mechanism of action, and clinical applications of tenofovir disoproxil fumarate.
• To examine clinical trial data and case reports concerning tenofovir-induced kidney injury.
• To discuss potential mechanisms of renal damage and provide management recommendations.

Main Methods:

• Literature review of clinical trials and case reports on tenofovir disoproxil fumarate.
• Analysis of pharmacokinetic and pharmacodynamic data.
• Discussion of reported adverse events and proposed mechanisms of renal toxicity.

Main Results:

• Tenofovir disoproxil fumarate demonstrates efficacy against HIV and HBV.
• Case reports have documented instances of tenofovir-induced renal tubular damage, Fanconi's syndrome, and diabetes insipidus.
• Potential mechanisms for renal damage are explored, linking to cellular processes within renal tubules.

Conclusions:

• While effective, tenofovir disoproxil fumarate carries a risk of nephrotoxicity, including specific renal syndromes.
• Understanding the pharmacokinetics and potential mechanisms of renal injury is crucial for patient management.
• Recommendations for the evaluation and treatment of tenofovir-induced kidney injury are provided to guide clinical practice.